RNXT Share Price Performance
US$0.96
-0.29 (-23.20%)
77.1% undervalued intrinsic discount
US$4.20
Fair Value
Price US$0.96
Stock_Research_Today US$4.20
Fair ValueUS$4.20
Share Pricen/a
RenovoRx, Inc. Stock Price
- 1 Narratives written by author
- 3 Comments on narratives written by author
- 239 Fair Values set on narratives written by author
RNXT Community Narratives
ST
Fair Value US$4.2 77.1% undervalued intrinsic discount
Revolutionizing Cancer Treatment
16users have liked this narrative
3users have commented on this narrative
129users have followed this narrative
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.Read more
16users have liked this narrative
3users have commented on this narrative
129users have followed this narrative
ST
US$4.2
77.1% undervalued intrinsic discount
Stock_Research_Today's Fair Value
Revenue
371.3% p.a.
Profit Margin
36%
Future PE
15x
Price in 2029
US$3.98
Trending Discussion
Recently Updated Narratives
ST
Revolutionizing Cancer Treatment
Fair Value: US$4.2 77.1% undervalued intrinsic discount
129 followersusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
RenovoRx, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.30
- 67.78%
- -1,196.66%
- 0%
About RNXT
- Founded
- 2009
- Employees
- 10
- CEO
- WebsiteView website
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
